Form 4: Director Equity Grant at Fate Therapeutics

Robert S. Epstein, a Director at Fate Therapeutics, Inc., received a grant of stock options.

Summary

• Robert S. Epstein, a Director at Fate Therapeutics, Inc. (FATE), was granted 87,900 stock options on June 12, 2026.
• The options have an exercise price of $2.06 per share.
• These options are part of an annual equity grant to non-employee directors under the company's compensation policy.
• The options will vest and become exercisable on June 12, 2027, or the date of the 2027 Annual Meeting of Stockholders, whichever comes first, provided Mr. Epstein continues to serve on the Board of Directors.
• Following the transaction, Mr. Epstein beneficially owns 87,900 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine director equity grant and does not contain new financial performance data or strategic announcements.

Positives

• Director compensation aligns with company policy, providing incentives for continued service.
• The grant of options suggests management's commitment to retaining experienced board members.
• The exercise price of $2.06 is below the current market price (assuming the filing date is after the grant date and the stock price has appreciated).

Negatives

• The filing only details a routine equity grant to a director and does not provide financial performance updates or strategic news.
• The value of the options is contingent on future stock performance and continued service.

Risks

• The vesting schedule is tied to continued service, meaning the options could be forfeited if the director resigns or is removed.
• The value of the options is subject to market volatility and the company's future performance.

Future Outlook

The future outlook for the granted options depends on the continued service of Robert S. Epstein and the future stock performance of Fate Therapeutics, Inc. The options are set to vest on June 12, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Management Comments

• The transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy.
• The policy provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
• The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the biotechnology and pharmaceutical sectors to align director interests with shareholder value and attract experienced leadership. This grant at Fate Therapeutics follows this industry norm.

Corporate Governance

Related Party Transactions

• The transaction involves a grant of stock options from Fate Therapeutics, Inc. to its Director, Robert S. Epstein, which is a standard related-party transaction governed by the company's compensation policy.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with shareholder interests, potentially leading to better long-term decision-making. However, the immediate impact on share price is minimal as it's a routine grant.
• Employees: The compensation structure for directors is separate from employee compensation, so direct impact is unlikely.
• Management: The grant reinforces the existing compensation structure for the board.

Next Steps

• Robert S. Epstein must continue his service on the Board of Directors until at least June 12, 2027, for the options to vest.
• The company will continue to operate under its Amended and Restated Non-Employee Director Compensation Policy for future annual equity grants.

Key Dates

Keywords

stock options, director compensation, equity grant, Fate Therapeutics, FATE, SEC Form 4, insider trading, beneficial ownership